Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease
Annals of Neurology · 2023-04 · 93 (4) · 819-829
DOI: 10.1002/ana.26588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 04.01.2023. Verfasst von Anna Rubinski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University, Munich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Neurodegenerative Erkrankungen.
Themen: Demenz
Abstract (Originalsprache)
Objective
Polygenic variation accounts for a substantial portion of the risk of Alzheimer's disease (AD), but its effect on the rate of fibrillar‐tau accumulation as a key driver of dementia symptoms is unclear.
Methods
We combined the to‐date largest number of genetic risk variants of AD (n = 85 lead single‐nucleotide polymorphisms [SNPs]) from recent genome‐wide association studies (GWAS) to generate a polygenic score (PGS). We assessed longitudinal tau‐positron emission tomography (PET), amyloid‐PET, and cognition in 231 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Using the PGS, together with global amyloid‐PET, we predicted the rate of tau‐PET increases in Braak‐stage regions‐of‐interest and cognitive decline. We also assessed PGS‐risk enrichment effects on the required sample size in clinical trials targeting tau pathology.
Results
We found that a higher PGS was associated with higher rates of tau‐PET accumulation, in particular at elevated amyloid‐PET levels. The tau‐PET increases mediated the association between PGS and faster cognitive decline. Risk enrichment through high PGS afforded sample size savings by 34%.
Interpretation
Our results demonstrate that the PGS predicts faster tau progression and thus cognitive decline, showing utility to enhance statistical power in clinical trials. ANN NEUROL 2023;93:819–829
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Stroke and Dementia Research, University Hospital, Ludwig Maximilian University, Munich, Germany.
- Graduate School of Systemic Neurosciences, Ludwig Maximilian University, Munich, Germany.
- Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Neurodegenerative diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany.
- Department of Psychiatry and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX.
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
ORCID-Profile: Simon Frerich, Nicolai Franzmeier, Alfredo Ramirez, Michael Ewers
Förderung
- NIA NIH HHS
- Deutsche Forschungsgemeinschaft
- Deutsches Zentrum für Neurodegenerative Erkrankungen
Zitieren
APA
Rubinski, A., Frerich, S., Malik, R., Franzmeier, N., Ramirez, A., Dichgans, M., Ewers, M., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2023). Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. Annals of Neurology, 93(4), 819-829. https://doi.org/10.1002/ana.26588
Vancouver
Rubinski A, Frerich S, Malik R, Franzmeier N, Ramirez A, Dichgans M, et al. Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease. Annals of Neurology. 2023;93(4):819-829. doi:10.1002/ana.26588
BibTeX
@article{Rubinski2023,
author = {Rubinski, Anna and Frerich, Simon and Malik, Rainer and Franzmeier, Nicolai and Ramirez, Alfredo and Dichgans, Martin and Ewers, Michael and Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer's Disease Neuroimaging Initiative (ADNI)},
title = {Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease},
journal = {Annals of Neurology},
year = {2023},
volume = {93},
number = {4},
pages = {819--829},
doi = {10.1002/ana.26588}
}
EUVIMED